In addition to this evidence supporting alterations in tau metabolism in sporadic ALS, a subset of CTE patients (in whom a tauopathy is the neuropathological hallmark) will have evidence of ALS either antemortem with clinical or electrophysiological evidence of diffuse motor neuron degeneration, or at autopsy (80, 81, 116). The gene discussed is MAPT; the disease is amyotrophic lateral sclerosis.